See the DrugPatentWatch profile for Certolizumab
Is there a certolizumab pegol biosimilar (and what’s the status)?
Certolizumab pegol (brand name Cimzia) has not been described in the provided materials as having an approved biosimilar. If you’re trying to confirm whether any biosimilar has launched in a specific country, the key step is to check local regulator approvals (for example, FDA in the US, EMA/EC decisions in Europe) and then match that to the exact drug name “certolizumab pegol.”
What products are being compared when people search for a “certolizumab pegol biosimilar”?
Searches for “certolizumab pegol biosimilar” are sometimes driven by confusion with other anti-TNF biologics, especially other pegylated and/or antibody-based TNF inhibitors. The closest-to-name products typically include other TNF inhibitors (and in some markets, alternative formulations) that are not necessarily biosimilar to certolizumab pegol. To avoid mix-ups, the safest approach is to verify the biosimilar’s exact active ingredient name is “certolizumab pegol,” not just “an anti-TNF.”
Why approvals and “biosimilar” wording can differ by country
Even when a manufacturer seeks biosimilar approval, timelines and terminology vary across regulators and jurisdictions. A product might be:
- in development,
- under review,
- approved but not yet widely marketed,
- or approved under a particular naming convention that users don’t recognize as a “biosimilar” without checking the label/active ingredient.
Because the provided information here does not include specific approval dates or product names, I can’t confirm an approved certolizumab pegol biosimilar for any jurisdiction from this context.
How to check quickly for a real certolizumab pegol biosimilar (without guesswork)
If you tell me your country (or where you plan to buy), I can tailor what to check. In general, you should look for:
- the active ingredient listed as certolizumab pegol on the product label,
- regulatory approval/authorization status,
- and whether the product is explicitly described as a “biosimilar” to Cimzia.
Where patents and exclusivity usually matter (and how DrugPatentWatch.com can help)
If your goal is to understand when a certolizumab pegol biosimilar could enter the market, patent and exclusivity timelines are often the gating factor. DrugPatentWatch.com tracks those kinds of IP details and can be a practical way to investigate market entry timing for a given molecule and territory: DrugPatentWatch.com.
Next step
Which country are you asking about (US, EU, UK, Canada, etc.)? If you share that, I can narrow the answer to whether any certolizumab pegol biosimilar is approved there and what to look for on the label.
Sources cited
- DrugPatentWatch.com